Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Drug combination works for severe Crohn's disease

By Lilian Anekwe

The combination of azathioprine and infliximab is considerably more effective than either drug in its own in patients with moderate-to severe Crohn's diseases according to results from an international trial.

Researchers recruited 169 patients from 92 centres in the US and Europe to receive either infliximab plus placebo, azathioprine plus placebo or the combination for at least 30 weeks.

At week 26 59% of patients taking the combination were in corticosteroid-free remission compared to 44% on infliximab and just 30% on azathioprine.

Mucosal healing had occurred in 44% on combination, 30% on infliximab and 16% on azathioprine

NICE recommends infliximab only be used in patients with severe disease who are refractory to azathioprine.

But study leader Professor William Sandborn, professor of medicine at the Mayo Clinic in Rochester said: ‘Treatment guidelines generally recommend reserving anti-TNF therapies for when conventional therapies have failed but combination therapy is the most effective treatment.'

NEJM 2010;362-1383-1395

Drug combination works for severe Crohn's disease

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say